Bard's bladder cancer test approved in Japan:
This article was originally published in Clinica
Executive Summary
CR Bard's BTA urine test for recurrent bladder cancer has been approved by the Japanese Ministry of Health and Welfare. The test, which has been shown to be more sensitive than urine cytology, will be used to monitor bladder cancer patients. It is already cleared for sale in the US and Europe and will be launched in June. Medicon, a joint-venture company of Bard, will sell the test in Japan.